This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2006 Jun;5(1):23-5.

doi: 10.1016/s1558-7673(11)70151-3.

Phase III study of sunitinib malate (SU11248) versus interferon-alpha as first-line treatment in patients with metastatic renal cell carcinoma

PMID: 16859575
DOI: 10.1016/s1558-7673(11)70151-3

Review

Phase III study of sunitinib malate (SU11248) versus interferon-alpha as first-line treatment in patients with metastatic renal cell carcinoma

Kesava Reddy. Clin Genitourin Cancer. 2006 Jun.

. 2006 Jun;5(1):23-5.

doi: 10.1016/s1558-7673(11)70151-3.

Author

PMID: 16859575
DOI: 10.1016/s1558-7673(11)70151-3

No abstract available

PubMed Disclaimer

Similar articles

[Sunitinib versus interferon-alpha in metastatic renal-cell carcinoma].
Irani J. Irani J. Prog Urol. 2007 Sep;17(5):996. doi: 10.1016/s1166-7087(07)92405-7. Prog Urol. 2007. PMID: 17969805 Clinical Trial. French. No abstract available.
[Sunitinib--from paradigm shift to standard treatment of metastatic renal cell carcinoma].
Bergmann L. Bergmann L. Onkologie. 2010;33 Suppl 1:2-4. doi: 10.1159/000265689. Epub 2010 Jan 22. Onkologie. 2010. PMID: 20164668 Review. German.
Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.
Négrier S, Bushmakin AG, Cappelleri JC, Korytowsky B, Sandin R, Charbonneau C, Michaelson MD, Figlin RA, Motzer RJ. Négrier S, et al. Eur J Cancer. 2014 Jul;50(10):1766-1771. doi: 10.1016/j.ejca.2014.03.012. Epub 2014 Apr 23. Eur J Cancer. 2014. PMID: 24768571
Long-term response with sunitinib for metastatic renal cell carcinoma.
Ronnen EA, Kondagunta GV, Ginsberg MS, Russo P, Motzer RJ. Ronnen EA, et al. Urology. 2006 Sep;68(3):672.e19-20. doi: 10.1016/j.urology.2006.03.042. Epub 2006 Sep 18. Urology. 2006. PMID: 16979716
Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.
Chouhan JD, Zamarripa DE, Lai PH, Oramasionwu CU, Grabinski JL. Chouhan JD, et al. J Oncol Pharm Pract. 2007 Mar;13(1):5-15. doi: 10.1177/1078155207077924. J Oncol Pharm Pract. 2007. PMID: 17621562 Review.

See all similar articles

Cited by

Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma.
Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN, Kahnoski R, Futreal PA, Furge KA, Teh BT. Huang D, et al. Cancer Res. 2010 Feb 1;70(3):1063-71. doi: 10.1158/0008-5472.CAN-09-3965. Epub 2010 Jan 26. Cancer Res. 2010. PMID: 20103651 Free PMC article.
Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines.
Pinkerneil M, Hoffmann MJ, Kohlhof H, Schulz WA, Niegisch G. Pinkerneil M, et al. Target Oncol. 2016 Dec;11(6):783-798. doi: 10.1007/s11523-016-0444-7. Target Oncol. 2016. PMID: 27250763 Free PMC article.
Immunotherapy for metastatic renal cell carcinoma.
Unverzagt S, Moldenhauer I, Nothacker M, Roßmeißl D, Hadjinicolaou AV, Peinemann F, Greco F, Seliger B. Unverzagt S, et al. Cochrane Database Syst Rev. 2017 May 15;5(5):CD011673. doi: 10.1002/14651858.CD011673.pub2. Cochrane Database Syst Rev. 2017. PMID: 28504837 Free PMC article.
First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis.
Aldin A, Besiroglu B, Adams A, Monsef I, Piechotta V, Tomlinson E, Hornbach C, Dressen N, Goldkuhle M, Maisch P, Dahm P, Heidenreich A, Skoetz N. Aldin A, et al. Cochrane Database Syst Rev. 2023 May 4;5(5):CD013798. doi: 10.1002/14651858.CD013798.pub2. Cochrane Database Syst Rev. 2023. PMID: 37146227 Free PMC article.
Heme oxygenase-1 is a predictive biomarker for therapeutic targeting of advanced clear cell renal cell carcinoma treated with sorafenib or sunitinib.
Zheng WX, Yan F, Xue Q, Wu GJ, Qin WJ, Wang FL, Qin J, Tian CJ, Yuan JL. Zheng WX, et al. Onco Targets Ther. 2015 Aug 10;8:2081-8. doi: 10.2147/OTT.S86222. eCollection 2015. Onco Targets Ther. 2015. PMID: 26309414 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information